IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
33.85
-0.72 (-2.08%)
At close: Jan 2, 2026, 4:00 PM EST
33.66
-0.19 (-0.56%)
After-hours: Jan 2, 2026, 7:44 PM EST
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $207.83M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $214.83M, up 5,377.66% year-over-year. In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%.
Revenue (ttm)
$214.83M
Revenue Growth
+5,377.66%
P/S Ratio
13.89
Revenue / Employee
$1,639,954
Employees
131
Market Cap
2.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IDYA News
- 22 days ago - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 23 days ago - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - PRNewsWire
- 4 weeks ago - IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away - Seeking Alpha
- 5 weeks ago - IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events - PRNewsWire